Evidence map›Paper›PMID 41128858›Full record

ArticleStrahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]2026

Longitudinal development and clinical predictors of financial toxicity among radiation oncology patients: final results of the SOCOFIN study.

Anna Luisa Kreuser, Sonia Ziegler, Stephanie Bendrich, Alexander Ziegler, Thomas Asendorf, Oliver Rick, Leif Hendrik Dröge, Martin Leu, Manuel Guhlich, Jan Oelmann and 5 more

Abstract read
In one paragraph

Article in Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anna Luisa KreuserDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany. annaluisa.kreuser@stud.uni-goettingen.de.ORCID 0009-0000-3658-0404
Sonia ZieglerDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Stephanie BendrichDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Alexander ZieglerDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Thomas AsendorfDepartment of Medical Statistics, University Medical Center Göttingen, Göttingen, Germany.
Oliver RickOncological Rehabilitation, Clinic of Reinhardshöhe, Bad Wildungen, Germany.
Leif Hendrik DrögeDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Martin LeuDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Manuel GuhlichDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Jan OelmannDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Laura Anna FischerDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Jann FischerDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Friederike BraulkeGöttingen-Comprehensive Cancer Center Göttingen, University Medical Center Göttingen, Göttingen, Germany.
Stefan RiekenDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.
Rami El ShafieDepartment of Radiation Oncology, University Medical Center Göttingen, Göttingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeFinancial toxicity (FT) associated with cancer and its treatment has become increasingly important. This study investigated factors associated with the development of FT during radiation therapy (RT). SOCOFIN was the first longitudinal prospective study to systematically evaluate FT in the context of RT.

methodsFinancial toxicity was measured with the Comprehensive Score for Financial Toxicity (COST-12) at RT initiation, completion, and at 3 months afterwards. Secondary endpoints included socioeconomic factors, health-related quality of life (EORTC QLQ-C30), depression (PHQ-9), coping mechanisms, and sense of coherence. The data were collected digitally; missing data were estimated using multiple imputation with chained equations.

resultsBetween July 2023 and June 2024, 230 patients were recruited. Analyses were performed on 170 records. During RT, FT did not increase; a slight overall decrease was descriptively observed. Of seven tumor groups, the highest difference in FT at baseline was measured between prostate (median 33) and pelvic cancer patients (median 19), reaching statistical significance (Kruskal-Wallis test, p = 0.01). Nonetheless, tumor entity was not found to be a significant predictor of FT following RT in multivariate linear regression models. While factors associated with FT differed between timepoints, financial difficulties at baseline predicted the occurrence of FT most strongly (p < 10

conclusionPredictors of FT were predominantly socioeconomic, such as baseline financial difficulties, net income, employment stability, and sense of coherence, which superseded tumor- or treatment-specific variables. The findings of this study underscore the necessity of multifactorial, early screening before RT to mitigate FT among radiation oncology patients.

Indexed as

Financial StressNeoplasmsRadiation OncologyAdaptation, PsychologicalAdultAgedFemaleGermanyHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesQuality of LifeSense of CoherenceSocioeconomic FactorsCancer survivorshipFinancial burdenRadiation therapySupportive care

Identifiers

PMID41128858
PMCPMC12953335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.